ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 573 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer
Adebrelimab Combined With Dalpicicliband Standard Endocrine Therapy for HR + / HER 2-breast Cancer:A Single-center,Open-label,Single-arm Clinical Trial
Who cites it
573 citing papers in PubMed, 5 syntheses or guidelines pooled it, 851 citations in OpenAlex.
- Efficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer: a meta-analysis of RCTs.Systematic reviews · 2026Pooled it
- Efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophagogastric junction or gastric cancer: a systematic review and meta analysis.Frontiers in immunology · 2026Pooled it
- Economic evaluations of neoadjuvant drug regimens in cancer: a systematic review.Frontiers in public health · 2026Pooled it
- Symptom clusters and their temporal patterns in breast cancer patients undergoing chemotherapy: a systematic review of cross-sectional and longitudinal studies.Frontiers in oncology · 2026Pooled it
- Immune checkpoint inhibitors plus chemotherapy for early-stage or locally -advanced triple-negative breast cancer: a systematic review and Bayesian network meta-analysis of randomized trials.Frontiers in oncology · 2026Pooled it
- Prospective comparison of [European journal of nuclear medicine and molecular imaging · 2026Trial
- Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple-negative breast cancer CALGB 40603 (Alliance).The Journal of clinical investigation · 2026Trial
- The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer.Breast cancer research : BCR · 2026Trial
- Neoadjuvant camrelizumab combined with metronomic chemotherapy in patients with advanced esophageal squamous cell carcinoma: a pilot randomized phase 2 trial.BMC medicine · 2026Trial
- PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.ESMO open · 2025Trial
- Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.International journal of cancer · 2025Trial
- High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.Breast cancer research : BCR · 2025Trial
- Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis.Signal transduction and targeted therapy · 2025Trial
- De-Escalation of Neoadjuvant Treatment for HER2-Positive Breast Cancer.International journal of cancer · 2026Review
- Lack of Utility of Ki-67 in Axillary Surgical Planning and Prognostication after Neoadjuvant Chemotherapy for Node-Positive Breast Cancer.Annals of surgical oncology · 2026Article
- Early Prediction of the Breast Cancer Response to Neoadjuvant Chemotherapy Based on Intratumoral Interstitial Fluid Pressure using 3-D Subharmonic-Aided Pressure Estimation.Ultrasound in medicine & biology · 2026Article
- Nodal Pathologic Response After Neoadjuvant Systemic Therapy in Clinically Advanced Node-Positive (cN2 and cN3) Breast Cancer.Annals of surgical oncology · 2026Article
- Development and evaluation of clinical models based on ultrasound, serum CA153 and molecular subtype in predicting the efficacy of neoadjuvant chemotherapy in breast cancer.Oncology letters · 2026Article
- Effect of Surgical Delay After Neoadjuvant Chemotherapy on Survival Outcomes in Breast Cancer: A Systematic Review and Meta-Analysis.European journal of breast health · 2026Article
- Predictive Value of CT-Derived Skeletal Muscle Metrics for Pathologic Complete Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.European journal of breast health · 2026Article
513 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Comment on
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
Abstract
purposeWhile various studies have highlighted the prognostic significance of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of additional adjuvant therapy after pCR is not known. EXPERIMENTAL
designPubMed was searched for studies with NAT for breast cancer and individual patient-level data was extracted for analysis using plot digitizer software. HRs, with 95% probability intervals (PI), measuring the association between pCR and overall survival (OS) or event-free survival (EFS), were estimated using Bayesian piece-wise exponential proportional hazards hierarchical models including pCR as predictor.
resultsOverall, 52 of 3,209 publications met inclusion criteria, totaling 27,895 patients. Patients with a pCR after NAT had significantly better EFS (HR = 0.31; 95% PI, 0.24-0.39), particularly for triple-negative (HR = 0.18; 95% PI, 0.10-0.31) and HER2
conclusionsAchieving pCR following NAT is associated with significantly better EFS and OS, particularly for triple-negative and HER2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.